Três impurezas no intervalo de 0,08%-0,12% por área de pico foram detectadas no ingrediente farmacêutico ativo, anastrazol, por cromatografia líquida de alta eficiência (CLAE) em fase-reversa isocrática. Essas impurezas foram isoladas por prep-CLAE e caracterizadas por CL-EM/EM, CG/EM e dados experimentais de RMN. Com base nos resultados obtidos a partir de diferentes experimentos espectroscópicos, essas impurezas foram caracterizadas como 2,2’-(5-((4H-1,2,4-triazol-4-il)metil)-1,3-fenileno)bis(2-metilpropanonitrila) (Impureza I), 2,2’-(5-metil-1,3-fenileno)bis(2-metilpropanonitrila) (Impureza II) e 2,2’-(5-(bromometil)-1,3-fenileno)bis(2-metilpropanonitrila) (Impureza III).
Three impurities ranging from 0.08%-0.12% by peak area in anastrozole active pharmaceutical ingredient were detected by simple isocratic reverse-phase high performance liquid chromatography (HPLC). These impurities were isolated by prep-HPLC and were characterized by LC-MS/MS, GCMS and NMR experimental data. Based on the results obtained from different spectroscopic experiments, these impurities have been characterized as 2,2’-(5-((4H-1,2,4-triazol-4-yl)methyl)-1,3-phenylene)bis(2-methylpropanenitrile) (Impurity I), 2,2’-(5-methyl-1,3-phenylene)bis(2-methylpropanenitrile) (Impurity II) and 2,2’-(5-(bromomethyl)-1,3-phenylene)bis(2-methyl-propanenitrile) (Impurity III).